In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines
Abstract Tyrosine kinase inhibitors (TKIs) are routinely prescribed for the treatment of non‐small cell lung cancer (NSCLC). As with all medications, patients can experience adverse events due to TKIs. Unfortunately, the relationship between many TKIs and the occurrence of certain adverse events rem...
Saved in:
Main Authors: | Linda Wanika (Author), Neil D. Evans (Author), Martin Johnson (Author), Helen Tomkinson (Author), Michael J. Chappell (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification of small cell lung cancer patients who are at risk of developing common serious adverse event groups with machine learning
by: Linda Wanika, et al.
Published: (2023) -
Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016) -
Tyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK)
by: Fernando Franco, et al.
Published: (2017) -
Transformation of adenocarcinoma into small cell lung cancer as one of the mechanisms of acquired resistance to anti-EGFR tyrosine kinase inhibitors
by: O. O. Kovalov, et al.
Published: (2024) -
EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors
by: Haiyan Xu, et al.
Published: (2022)